Pharma News

People with neurofibromatosis type 1 (NF1) develop tumors on nerves throughout their bodies. These tumors are usually benign — meaning they don’t spread to other parts of the body and are not considered life-threatening — but they can still cause serious medical problems such as blindness, especially when they form in the brain and nerves.

New research from the University of Illinois suggests high levels of dietary cholesterol make mice sicker when infected with influenza. The study is the first to link cholesterol in the diet with exacerbation of a viral infection.

CSIR-CCMB has developed an ingenious mRNA vaccine against COVID-19 which has completed experiments in the lab and on mice. It is based on the Moderna model, but has been built with the information available in the open and CCMB technology and materials.

PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO) announced a major expansion of capabilities and capacity in aseptic liquid fill-finish and sterile lyophilization technology, an important manufacturing process commonly used with injectable and biologic therapies, with the investment of 100 Million USD into the construction and enhancement of world-class facilities, at its Bedford, New Hampshire campus.

Stroke is India’s third leading cause of death and the sixth leading cause of disability. Physiotherapy is one of the few treatments available for rehabilitating stroke victims and patients with physical injuries. However, physiotherapy can take days to months depending on the severity of the disability, making it challenging for patients as well as their attendants.

UNC School of Medicine Scientists have shown for the first time that postnatal gene therapy may be able to prevent or reverse many deleterious effects of a rare genetic disorder called Pitt-Hopkins syndrome. This autism spectrum disorder features severe developmental delay, intellectual disability, breathing and movement abnormalities, anxiety, epilepsy, and mild but distinctive facial abnormalities.

Aurobindo Pharma receives 6 observations after inspection of Aurobindo Pharma Jedcherla plant.

The United States Food and Drug Administration (US FDA) inspected Aurobindo Pharma's Unit VII, an oral manufacturing facility situated at Jedcherla, Hyderabad, from 2nd to 10th May 2022.

US FDA has conducted a Good Manufacturing Practices (GMP) inspection of Sun Pharmaceutical Industries Limited Halol facility Gujarat from April 26 to May 9, 2022. At the conclusion of the inspection, the US FDA issued a Form-483, with 10 observations.

US Pharma giant Pfizer has set up its global drug development centre at the Indian Institute of Technology-Madras Research Park with an investment of around 150 crore. This facility employs more than 250 scientists and professionals from a range of scientific disciplines, including Formulation Scientists and Pharmacists, Analytical Scientists, Life Science specialists such as Microbiologists and Biotechnologists, Chemical Engineers, Data Scientists and Program Managers.